Navigation Links
Cytonus Therapeutics Announces Christopher Thorne as Chairman
Date:1/27/2020

Cytonus Therapeutics Inc. today announced the appointment of Christopher Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former senior management consultant at McKinsey & Company who holds three Harvard degrees. He serves as Executive Chairman of Broadline Capital, the global alternative investment firm.

“Chris Thorne has exceptional business acumen with a proven track record in developing purpose-led businesses, driving innovation, and reinforcing a commitment to corporate responsibility,” commented Cytonus’ Founder and CEO, Remo Moomiaie-Qajar, MD. “He has extensive directorship experience at both publicly-listed corporations and privately-held ventures, as well as 501(c)(3) nonprofit organizations. All of these attributes, combined with his excellent people engagement and strategic insight, gives us confidence that Chris will help build a strong culture as we work together toward our shared vision for the Company and accelerate the development of our innovative platform of products to improve the health and lives of people across the globe.”

“Cytonus is delighted to have appointed Chris Thorne as our Chairman after a thorough and rigorous selection process,” commented Cytonus’ Founder and Chief Scientific Officer, Richard Klemke, PhD. “Chris is an outstanding leader who brings vast experience across multiple industries, from his career at McKinsey & Company, to his accomplishments as a visionary entrepreneur, and his success as an astute investor.”

Mr. Thorne will lead Cytonus’ corporate board of directors and will serve as an independent non-executive director for the company.

About Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is the cell-based platform technology company whose next-generation Adoptive Cellular Therapy (ACT) technologies have a wide range of medical applications across multiple therapeutic areas. Cytonus is developing a vast platform of proprietary immunotherapeutic products to cure a wide range of medical conditions including difficult-to-treat cancers and inflammatory diseases, and to improve patient outcomes. Its portfolio of inventions addresses the recognized limitations of existing cell-based therapies. Its proprietary pipeline of Cargocyte™ technologies are cellular-engineered enucleated transporters of a multiplicity of therapeutic payloads to tissue in selective, potent, and controllable off-the-shelf cellular therapies for treating numerous targeted diseases. Cytonus’ new category-creating technologies are expected to transform how cancers and other diseases will be treated in the future and have the potential to improve the health and lives of millions of people around the world. For more information, please visit the Cytonus website at https://Cytonus.com and follow our LinkedIn and Twitter feeds at: @Cytonus.

Statements in this news release relating to Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Follow Cytonus on LinkedIn and Twitter at: @Cytonus.

Read the full story at https://www.prweb.com/releases/cytonus_therapeutics_announces_christopher_thorne_as_chairman/prweb16858313.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology news :

1. Drug development venture links translational research, business to launch new therapeutics
2. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
3. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
4. Natura Therapeutics product shown to improve decision making skills in older adults
5. Emerging class of therapeutics represents a coming wave for developers and manufacturers
6. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
9. Industry group release testing recommendations for oligonucleotide-based therapeutics
10. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
11. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2020)... ... February 05, 2020 , ... ... greater ease, efficiency and insight to sample processing within laboratories. , Built ... laboratories conducting research in various fields, LabKey Sample Manager has been designed with ...
(Date:1/29/2020)... ... January 29, 2020 , ... ... it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV) ... Pharmaceuticals. A grant of up to $9 million from the Coalition for Epidemic ...
(Date:1/24/2020)... ... January 24, 2020 , ... Shoreline Biome , ... strain level, today announced that the company will debut a novel new DNA isolation ... , The new product, Shoreline Biome's Rapid Prep kit, is a fast and easy-to-use ...
Breaking Biology News(10 mins):
(Date:1/8/2020)... ... January 08, 2020 , ... Anomet Products ... properties for use in harsh environments inside or outside of the human body. ... metals or alloys to achieve specific properties such as corrosion-resistance, biocompatibility, or operation ...
(Date:1/7/2020)... (PRWEB) , ... January 06, 2020 , ... ... a Digital World at The Fletcher School at Tufts University, is pleased to ... Foundation. The grant will be administered by Tufts University, and will help to ...
(Date:12/31/2019)... ... 2019 , ... At this year's SLAS conference, Visikol will present several talks ... 3D cell culture , advanced imaging and multiplex analysis . Specifically, ... steatosis , inflammation and fibrosis as well as a 2D cell culture ...
(Date:12/23/2019)... N.J. (PRWEB) , ... December 23, 2019 , ... ... based leak detection systems for the Pharmaceutical, Biotechnology and Medical Device Industries, is ... presenter at the Parenteral Drug Association (PDA) Container Closure Integrity Testing Basic ...
Breaking Biology Technology: